Fox Chase Cancer Center Details Findings in Carcinomas (Pembrolizumab Plus Axitinib Versus Sunitinib As First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 Keynote-426 Study)

Press/Media

PeriodNov 29 2023

Media coverage

1

Media coverage

  • TitleFox Chase Cancer Center Details Findings in Carcinomas (Pembrolizumab Plus Axitinib Versus Sunitinib As First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 Keynote-426 Study)
    Media name/outletImmunotherapy Daily
    Country/TerritoryUnited States
    Date11/29/23
    PersonsElizabeth R. Plimack